Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Imuno Therapeutics logo — Identifying true targets in oncology and autoimmune disorder...

Imuno Therapeutics

Identifying true targets in oncology and autoimmune disorders

Founded 2020 The Netherlands The Netherlands 11 employees Seed Health Care, Health and Wellness

General Information

Company Name Imuno Therapeutics
Founded Year 2020
Location The Netherlands The Netherlands
Employees 11
Industries Health Care, Health and Wellness
Funding Stage Seed
Business Model B2B, D2C, Platform
Revenue Model Licensing, Performance Based, Service Fee
Offices as of Oct 2026
Leiden, The Netherlands
Social

BounceWatch is an independent company data service, not affiliated with Imuno Therapeutics. To contact Imuno Therapeutics, visit imunotx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Imuno Therapeutics compare?

A PDF of Imuno Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Imuno Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Imuno Therapeutics

Imuno Therapeutics, founded in 2020 and headquartered in The Netherlands, is at the forefront of leveraging machine learning for drug discovery in the fields of oncology and autoimmune disorders. Their slogan, "Identifying true targets in oncology and autoimmune disorders," encapsulates their innovative approach.

The company has developed a cutting-edge, structure-based discovery engine designed to identify cancer-specific epitopes. This technology not only focuses on epitopes uniquely specific to an individual patient’s tumor but also pinpoints those with optimal properties for therapeutic targeting, potentially revolutionizing personalized cancer treatment.

Operating within the Health Care and Health and Wellness sectors, Imuno Therapeutics represents a promising opportunity for investors interested in pioneering medical technology. While the company is yet to disclose its latest investment details, its innovative approach is likely to attract forward-thinking investors aiming to impact the future of personalized medicine.

Business keywords: structure-based discovery, cancer-specific epitopes, therapeutic targeting, novel therapeutic strategies, oncology, autoimmune disorders, cross-reactive epitopes, in-vitro safety studies, personalized medicine, tumor-specific therapy, drug discovery, bioinformatics, epitope identification, safe therapies development

Services & Products

Development of next-generation immunotherapies
Engineering precision-targeted intracellular antigen therapies
Partnering for immunotherapy advancements

Target Customers

Patients with hard-to-treat diseases Oncology and autoimmune disease communities Biotechnology and pharmaceutical partners

No funding data available for Imuno Therapeutics yet.

Imuno Therapeutics Alternatives & Competitors

View All Alternatives
Imuno Therapeutics vs
Rgenta Therapeutics Inc.
Rgenta Therapeutics Inc. United States

We unlock the therapeutic potentials of highly disease-relevant targets undruggable by small molecul...

Series A
33 employees
Biotechnology, Health Care
Imuno Therapeutics vs
Nimbus Therapeutics
Nimbus Therapeutics United States

We develop breakthrough medicines for patients through precision small molecule design.

103 employees
Biotechnology, Health Care
Imuno Therapeutics vs
Ikena Oncology (Merged with ImageneBio)
Ikena Oncology (Merged with ImageneBio) United States

Ikena merged with ImageneBio on in July 2025. Please visit https://inmagenebio.com/ for more informa...

Post-IPO Equity
14 employees
Biotechnology, Health Care
View all alternatives

FAQ About Imuno Therapeutics

Identifying true targets in oncology and autoimmune disorders
Imuno Therapeutics was founded in 2020.
Imuno Therapeutics is headquartered in The Netherlands. As of Oct 2026, it also has offices in Leiden, The Netherlands.
Imuno Therapeutics operates in Health Care and Health and Wellness. Its work centres on structure-based discovery, cancer-specific epitopes, therapeutic targeting and novel therapeutic strategies. Its customers include Patients with hard-to-treat diseases, Oncology and autoimmune disease communities and Biotechnology and pharmaceutical partners.
Imuno Therapeutics has a B2B, D2C and Platform business model. Its revenue comes from Licensing, Performance Based and Service Fee.
Imuno Therapeutics has approximately 11 employees.
Imuno Therapeutics offers: Development of next-generation immunotherapies, Engineering precision-targeted intracellular antigen therapies, Partnering for immunotherapy advancements.
Top alternatives and competitors to Imuno Therapeutics include Rgenta Therapeutics Inc., Nimbus Therapeutics, Ikena Oncology (Merged with ImageneBio), Gritstone bio, Breakpoint Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Imuno Therapeutics and Rgenta Therapeutics Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Imuno Therapeutics, https://bouncewatch.com/company/imuno-therapeutics, updated 5 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout